On June 3, Li Dianxun, Deputy Secretary of the Provincial Party Committee and Governor, visited Hubei Zhongyao Pharmaceutical Co., Ltd. for an inspection. He conducted an in-depth review of the company’s research and development of traditional Chinese medicine, the operation of its production lines, and its overall business and operational status. By precisely identifying the pain points and challenges hindering the company’s growth, he provided clear guidance, defined a strategic path, and set specific requirements for its high-quality, sustainable development. Vice Governor Li Donghui participated in the inspection, accompanied by officials from Enshi Prefecture and Xuan'en County.
During the research visit, Li Dianxun and his delegation toured the company’s traditional Chinese medicine (TCM) product exhibition area and production workshops. They gained a detailed understanding of how the company leverages the authentic TCM resources of Enshi to focus on two core business areas: TCM formula granules and high-end prepared TCM slices (*yinpian*). Li listened attentively to a comprehensive report on the company’s initiatives, including the development of specialized TCM resources, the iteration of core products, the expansion of production capacity, and the broadening of market channels. He inquired specifically about the company’s progress—as well as the challenges it faces—regarding technological innovation, industry-academia-research collaboration, product standardization, and market promotion. Li highly commended Zhongyao Pharmaceutical for capitalizing on local resource advantages and focusing on the refined, high-end development of TCM, noting the significant progress and industrial achievements the company has made in the fields of formula granules and high-end prepared slices.
Taking into account both industry trends and the company’s current operational reality, Li Dianxun provided key guidance and set clear requirements for the future development of Zhongyao Pharmaceutical:
First, the company should leverage its resource endowments to solidify the foundation for industrial development. Li pointed out that Enshi Prefecture boasts an excellent ecological environment and an abundance of high-quality TCM resources—a core competitive advantage and a valuable asset for the TCM industry. The company should firmly capitalize on these local resources, exploring and utilizing them efficiently to transform high-quality ecological assets into high-quality industrial and product resources, thereby continuously strengthening its core foundation.
Second, the company should prioritize innovation-driven growth and deepen its commitment to product R&D. Li emphasized that technological innovation is the primary pillar for the modernization and high-quality development of the TCM industry. The company must reinforce its role as the principal driver of innovation, deepen collaborative efforts with universities and research institutions, and focus its resources on critical areas such as pharmacological research, the establishment of quality standard systems, and the iteration and upgrading of products. By enhancing the technological content, core competitiveness, and clinical utility of its offerings, the company can use innovation to drive quality improvements and greater efficiency.
Third, the company should broaden its development horizons and elevate its brand profile. Li urged the company to adopt a long-term, holistic perspective; while firmly consolidating its foundations in R&D, production, and quality control, it should also proactively engage with both domestic and international markets. We will strictly control product quality standards, continuously optimize our product portfolio, and cultivate a distinctive brand identity. By integrating the entire value chain—encompassing resources, products, the market, and the brand—we aim to transform our resource advantages into competitive strengths in products, market presence, and brand recognition, ultimately enhancing quality and efficiency while scaling up the enterprise.
The Governor’s visit serves as both a strong endorsement of Zhongyao Pharmaceutical’s achievements and a powerful source of encouragement and empowerment for the company as it deepens its commitment to the traditional Chinese medicine (TCM) industry and contributes to the high-quality development of local specialized sectors. Moving forward, Zhongyao Pharmaceutical will diligently implement the directives provided during the visit. We will remain focused on our strategic goals and key tasks, prioritize innovation within our core business, and strive to elevate the company to new heights—thereby making a greater contribution to the upgrading of the TCM industry in Enshi and the high-quality development of the TCM sector across Hubei Province.
The company will resolutely carry out the instructions of Governor Li Dianxun, adhering to a development strategy of "inheriting the essence while upholding integrity and fostering innovation":
1.Deepening Collaborative Innovation: We will proactively engage with universities and research institutions to accelerate the translation of pharmacological research on traditional Chinese medicines. Furthermore, by collaborating with Marketing Authorization Holder (MAH) platforms, we will advance the standardization of key products and the development of new drugs.
2.Strict Quality Control: We will maintain rigorous quality oversight across the entire value chain—from cultivation at the source to final processing—by establishing internal control standards that exceed industry benchmarks.
3.Expanding Market Reach: Rooted in Hubei and extending our footprint nationwide, we will explore new models that integrate online and offline channels. We will also pursue opportunities in overseas markets, dedicated to bringing "quality medicine from Enshi" to a broader stage.
